BR112019022280A2 - tratamento de cânceres de her2 positivo - Google Patents

tratamento de cânceres de her2 positivo Download PDF

Info

Publication number
BR112019022280A2
BR112019022280A2 BR112019022280A BR112019022280A BR112019022280A2 BR 112019022280 A2 BR112019022280 A2 BR 112019022280A2 BR 112019022280 A BR112019022280 A BR 112019022280A BR 112019022280 A BR112019022280 A BR 112019022280A BR 112019022280 A2 BR112019022280 A2 BR 112019022280A2
Authority
BR
Brazil
Prior art keywords
positive cancer
her2 positive
cancer treatment
individual
comprises administering
Prior art date
Application number
BR112019022280A
Other languages
English (en)
Inventor
Walker Luke
Peterson Scott
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of BR112019022280A2 publication Critical patent/BR112019022280A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

em um aspecto, a presente invenção refere-se a um método para o tratamento ou melhora dos efeitos de um câncer her2 positivo em um indivíduo. em algumas modalidades, o método compreende administrar uma terapia de combinação compreendendo um anticorpo anti-her2 e tucatinibe. em algumas modalidades, o método também compreende administrar um agente quimioterapêutico (por exemplo, um antimetabólito) ao indivíduo. as composições farmacêuticas e kits são também fornecidos aqui.
BR112019022280A 2017-04-28 2018-04-27 tratamento de cânceres de her2 positivo BR112019022280A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491872P 2017-04-28 2017-04-28
PCT/US2018/029899 WO2018201016A1 (en) 2017-04-28 2018-04-27 Treatment of her2 positive cancers

Publications (1)

Publication Number Publication Date
BR112019022280A2 true BR112019022280A2 (pt) 2020-05-19

Family

ID=62165692

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019022280A BR112019022280A2 (pt) 2017-04-28 2018-04-27 tratamento de cânceres de her2 positivo

Country Status (13)

Country Link
US (3) US11207324B2 (pt)
EP (1) EP3615067A1 (pt)
JP (2) JP7328151B2 (pt)
KR (1) KR20200014298A (pt)
CN (1) CN111032082A (pt)
AU (2) AU2018258663B2 (pt)
BR (1) BR112019022280A2 (pt)
CA (1) CA3060407A1 (pt)
EA (1) EA201992573A1 (pt)
MA (1) MA49059A (pt)
SG (1) SG11201909676WA (pt)
WO (1) WO2018201016A1 (pt)
ZA (1) ZA201907225B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49059A (fr) 2017-04-28 2021-03-24 Seagen Inc Traitement des cancers positifs à her2
TW202042820A (zh) * 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
WO2020251556A1 (en) 2019-06-11 2020-12-17 Io Therapeutics, Inc. Use of an rxr agonist in treating her2+ cancers
MX2022004699A (es) * 2019-10-21 2022-08-08 Seagen Inc Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab.
MX2022014886A (es) * 2020-05-29 2023-01-04 Seagen Inc Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.
KR20230078705A (ko) * 2020-09-28 2023-06-02 씨젠 인크. 항-her2 항체와 병용된 투카티닙으로 her2 변형에 의해 유도된 고형 종양을 치료하는 방법
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
US11526994B1 (en) * 2021-09-10 2022-12-13 Neosoma, Inc. Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
DE69311538D1 (de) 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
CN102432552B (zh) 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CA2569132A1 (en) 2004-06-03 2005-12-22 Smithkline Beecham (Cork) Limited Cancer treatment method
CA2755268C (en) 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
JP2010540460A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
HUE035605T2 (en) * 2009-11-13 2018-05-28 Daiichi Sankyo Europe Gmbh Materials and Methods for the Treatment or Prevention of HER-3-Related Diseases
CA2835284C (en) * 2011-05-19 2020-08-25 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
CA2852060A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
SG11201401459YA (en) 2011-10-14 2014-07-30 Array Biopharma Inc Solid dispersions of a erb2 (her2) inhibitor
EP4252855A3 (en) 2012-03-23 2023-11-15 Array Biopharma, Inc. Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
US20190119284A1 (en) * 2016-04-19 2019-04-25 The Regents Of The University Of California ErbB Inhibitors and Uses Thereof
MA49059A (fr) 2017-04-28 2021-03-24 Seagen Inc Traitement des cancers positifs à her2
EP3807640A4 (en) 2018-06-14 2022-04-13 Memorial Sloan Kettering Cancer Center METHOD OF PREDICTING THE SENSITIVITY OF LUNG CANCER PATIENTS TO HER2 TARGETING THERAPY
TW202042820A (zh) 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
MX2022004699A (es) 2019-10-21 2022-08-08 Seagen Inc Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab.
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
US20230136203A1 (en) 2020-03-11 2023-05-04 Seagen Inc. Methods of treating her2 mutant cancers with tucatinib

Also Published As

Publication number Publication date
SG11201909676WA (en) 2019-11-28
AU2018258663A1 (en) 2019-11-14
CN111032082A (zh) 2020-04-17
WO2018201016A1 (en) 2018-11-01
ZA201907225B (en) 2023-11-29
MA49059A (fr) 2021-03-24
US11666572B2 (en) 2023-06-06
EA201992573A1 (ru) 2020-04-06
US20200188401A1 (en) 2020-06-18
US20230390290A1 (en) 2023-12-07
AU2018258663B2 (en) 2022-08-04
CA3060407A1 (en) 2018-11-01
US11207324B2 (en) 2021-12-28
AU2022241509A1 (en) 2022-10-27
JP7328151B2 (ja) 2023-08-16
EP3615067A1 (en) 2020-03-04
US20220168303A1 (en) 2022-06-02
KR20200014298A (ko) 2020-02-10
JP2020517696A (ja) 2020-06-18
JP2023145689A (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
PH12018500642A1 (en) Anti-garp antibody
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112019005305A2 (pt) compostos espirocíclicos
EA201892229A1 (ru) Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением
BR112015016466A2 (pt) método para o tratamento de câncer baseado no estado de mutação de k-ras
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
EA202091514A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112016028641A2 (pt) ?método para tratar câncer?
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018076639A2 (pt) quimioterapias de combinação
BR112019006329A2 (pt) métodos de tratamento de câncer do trato biliar
BR112022008365A2 (pt) Inibidores de cd73
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
BR112019011350A2 (pt) terapia de combinação
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SEAGEN INC. (US)